Browsing by Author "Stroux, Andrea (10139008600)"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Early NT-proBNP and MR-proANP associated with QoL 1 year after acutely decompensated heart failure: secondary analysis from the MOLITOR trial(2019) ;Zelenak, Christine (36873788500) ;Chavanon, Mira-Lynn (14048024000) ;Tahirovic, Elvis (24339336300) ;Trippel, Tobias Daniel (16834210300) ;Tscholl, Verena (54982696400) ;Stroux, Andrea (10139008600) ;Veskovic, Jovan (56951285600) ;Apostolovic, Svetlana (13610076800) ;Obradovic, Danilo (35731962400) ;Zdravkovic, Marija (24924016800) ;Loncar, Goran (55427750700) ;Störk, Stefan (6603842450) ;Herrmann-Lingen, Christoph (6603417225)Düngen, Hans-Dirk (16024171900)Aim: Heart failure negatively impacts quality of life (QoL), which in turn contributes to an adverse long-term prognosis. We aimed at identifying biomarker trajectories after an episode of acutely decompensated heart failure (ADHF) that differ between patients showing average versus impaired QoL 1 year later, thus allowing to predict impaired QoL. Methods: Biomarkers were repeatedly measured throughout the year in 104 ADHF patients. QoL was assessed at discharge and 1 year after ADHF. Logistic regression and receiver operating characteristic analyses were used to identify predictors of impaired QoL while controlling psychosocial confounders. Results: MR-proANP predicted impaired physical and mental QoL. NT-proBNP measurements were important predictors for poor physical QoL. Conclusion: MR-proANP and NT-proBNP predict poor QoL after an epidode of ADHF. The trial is registered at http://clinicaltrials.gov as MOLITOR (IMpact of therapy optimisation On the Level of biomarkers in paTients with Acute and Decompensated ChrOnic HeaRt Failure) with unique identifier: NCT01501981. © 2019 Future Medicine Ltd. - Some of the metrics are blocked by yourconsent settings
Publication Early NT-proBNP and MR-proANP associated with QoL 1 year after acutely decompensated heart failure: secondary analysis from the MOLITOR trial(2019) ;Zelenak, Christine (36873788500) ;Chavanon, Mira-Lynn (14048024000) ;Tahirovic, Elvis (24339336300) ;Trippel, Tobias Daniel (16834210300) ;Tscholl, Verena (54982696400) ;Stroux, Andrea (10139008600) ;Veskovic, Jovan (56951285600) ;Apostolovic, Svetlana (13610076800) ;Obradovic, Danilo (35731962400) ;Zdravkovic, Marija (24924016800) ;Loncar, Goran (55427750700) ;Störk, Stefan (6603842450) ;Herrmann-Lingen, Christoph (6603417225)Düngen, Hans-Dirk (16024171900)Aim: Heart failure negatively impacts quality of life (QoL), which in turn contributes to an adverse long-term prognosis. We aimed at identifying biomarker trajectories after an episode of acutely decompensated heart failure (ADHF) that differ between patients showing average versus impaired QoL 1 year later, thus allowing to predict impaired QoL. Methods: Biomarkers were repeatedly measured throughout the year in 104 ADHF patients. QoL was assessed at discharge and 1 year after ADHF. Logistic regression and receiver operating characteristic analyses were used to identify predictors of impaired QoL while controlling psychosocial confounders. Results: MR-proANP predicted impaired physical and mental QoL. NT-proBNP measurements were important predictors for poor physical QoL. Conclusion: MR-proANP and NT-proBNP predict poor QoL after an epidode of ADHF. The trial is registered at http://clinicaltrials.gov as MOLITOR (IMpact of therapy optimisation On the Level of biomarkers in paTients with Acute and Decompensated ChrOnic HeaRt Failure) with unique identifier: NCT01501981. © 2019 Future Medicine Ltd.
